As of Nov 27
| +0.01 / +0.12%|
The 2 analysts offering 12-month price forecasts for Ocata Therapeutics Inc have a median target of 8.25, with a high estimate of 8.50 and a low estimate of 8.00. The median estimate represents a -3.62% decrease from the last price of 8.56.
The current consensus among 3 polled investment analysts is to Hold stock in Ocata Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.